Kinnate Biopharma (KNTE) Social Stream
Kinnate Biopharma Inc (KNTE) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Kinnate Biopharma Inc.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-10-28 | 6 | $52 | $32 | $46.4 | $10.97 | 322.97% |
| 2021-11-11 | 6 | $53 | $32 | $47 | $10.97 | 328.44% |
| 2022-02-02 | 6 | $52 | $35 | $45.8 | $10.97 | 317.5% |
| 2022-03-29 | 6 | $52 | $33 | $41 | $10.97 | 273.75% |
The Trend in the Analyst Price Target
KNTE's average price target has moved down $4.4 over the prior 152 days.
KNTE reports an average of 150.74% for its upside potential over the past 49 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-05-15 | 3 | 52 | 48 | 50.5 | 22.74 | 122.08% |
| 2021-07-24 | 4 | 52 | 50 | 51.0 | 22.00 | 131.82% |
| 2021-08-10 | 4 | 52 | 50 | 51.0 | 21.08 | 141.94% |
| 2021-09-04 | 4 | 52 | 50 | 51.0 | 23.73 | 114.92% |
| 2022-03-29 | 6 | 52 | 33 | 41.0 | 13.06 | 213.94% |
KNTE Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 6 | 0 | 0 | 0 | 0 | 6 |
The Trend in the Broker Recommendations
Over the past 120 days, KNTE's average broker recommendation rating improved by 0.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for KNTE as an investment opportunity.
- Kinnate Biopharma Inc's upside potential (average analyst target price relative to current price) is greater than 464.59% of all US stocks.
- To contextualize these metrics, consider that out of stocks in the small market cap category, Kinnate Biopharma Inc's average analyst price target is greater than 420.6% of them.
- In the context of stocks in the small market cap category, Kinnate Biopharma Inc's number of analysts covering the stock is higher than 389.5% of them.
- In the context of Pharmaceutical Products stocks, Kinnate Biopharma Inc's variance in analysts' estimates is lower than -79.72% of them.
Stocks similar to Kinnate Biopharma Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are KNSA, KMPH, and KMDA.
Make investment decisions regarding KNTE using the data that counts. Try POWR Ratings for free.